Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
21 mars 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
14 mars 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 mars 2022 17h20 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 10, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
01 mars 2022 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, March 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
28 févr. 2022 06h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO and NAGOYA, Japan, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and...
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
09 févr. 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 févr. 2022 16h42 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
12 janv. 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with...
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
05 janv. 2022 07h30 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
18 nov. 2021 08h00 HE
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...